CARsgen Therapeutics Holdings Limited has achieved a significant victory concerning its European patent for a GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology firm withdrew its appeal against the European Patent Office (EPO) decision to maintain the patent, effectively finalizing the ruling in CARsgen’s favor. This outcome strengthens the company’s intellectual property rights and supports its ongoing development of innovative cancer therapies.
In 2022, the EPO granted patent EP3445407, which covers the use of GPC3-targeted CAR-T cell therapy, a treatment aimed at various solid tumors, including liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. The patent faced opposition from two parties in 2023. Following oral proceedings, the EPO maintained the patent in an amended form, upholding critical claims related to the therapy’s administration following lymphodepletion pretreatment with cyclophosphamide and fludarabine.
The withdrawal of the appeal by the remaining opponent means that no further challenges can be made against the patent under EPO procedures. This resolution marks a pivotal moment for CARsgen as it seeks to advance its GPC3-targeted CAR-T therapies, which hold promise in treating solid tumors that have proven difficult to manage with existing treatments.
About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company headquartered in Shanghai, focusing on the development of innovative CAR T-cell therapies. The company aims to address unmet clinical needs across a range of conditions, including hematologic malignancies, solid tumors, and autoimmune diseases. CARsgen has established comprehensive capabilities in CAR T-cell research and development, covering everything from target discovery to commercial-scale production.
The company is dedicated to developing novel technologies and a robust product pipeline that tackles challenges faced by current CAR T-cell therapies. These efforts include enhancing safety profiles, improving efficacy against solid tumors, and reducing treatment costs. CARsgen aspires to become a global leader in biopharmaceuticals by delivering innovative and differentiated cell therapies that aim to make cancer and other diseases curable.
As CARsgen continues its mission, this patent victory serves as a testament to its commitment to advancing cutting-edge therapies for patients worldwide. For more information about CARsgen Therapeutics, visit their official website at https://www.carsgen.com.
“This development further reinforces CARsgen’s position in the field of GPC3-targeted CAR-T therapies,” said a company spokesperson.
This news highlights a critical advancement in CARsgen’s journey and reflects the broader potential of CAR-T cell therapies in oncology. The company remains poised to make significant contributions to the treatment of cancer, offering hope to patients facing challenging diagnoses.